Aaron N. Hata

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• <b>Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS</b>^{<strong>G12C</strong>}<b> inhibitors</b>

  Figshare · 2026-05-07

• <b>Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS</b>^{<strong>G12C</strong>}<b> inhibitors</b>

  Figshare · 2026-05-07

• Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS ^G12C suppresses PI3Kα and leads to potent tumor inhibition

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-04-30 · 1 citations

• Abstract 6773: Targeted therapy-induced chromosomal instability dictates mitotic dependency on Aurora kinase A

  Cancer Research · 2026-04-03

• Abstract 1062: Longitudinal monitoring of circulating tumor cells (CTC) reveals dynamic CTC behaviors associated with disease progression and survival in ALK-positive NSCLC

  Cancer Research · 2026-04-03

• Abstract 289: Tracking APOBEC3A to overcome drug resistance in lung cancer.

  Cancer Research · 2026-04-03

• Abstract 3536: Quantifying evolutionary dynamics and tumor heterogeneity in oncogene-addicted advanced non-small cell lung cancer

  Cancer Research · 2026-04-03

• Abstract 1870: Characterizing drug-induced transcriptional reprogramming in KRAS mutant lung cancer.

  Cancer Research · 2026-04-03

• Abstract 5787: TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors

  Cancer Research · 2026-04-03

• Abstract 7303: Activation of HIF1ɑ drives oxidative stress and promotes deep senescence in <i>EGFR</i> -mutant NSCLC drug tolerant persister cells

  Cancer Research · 2026-04-03

• Figure S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Table S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Table S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Table S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S4 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• Figure S5 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer

  2026-03-16

• ApoFLARE: a luminescent reporter for direct quantification of APOBEC3A editing activity

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-03-14

• Abstract B018: ZNF384 Orchestrates Cell-State Reprogramming and Kinome Remodeling in KRAS G12C Inhibitor Resistance

  Cancer Research · 2026-03-05